• SERVICES
  • INDUSTRIES
  • PERSPECTIVES
  • ABOUT
  • ENGAGE

CHINA

by EOS Intelligence EOS Intelligence No Comments

Traditional Chinese Medicine: Ready for the Global Stage?

427views

In late 2015, Chinese researcher Tu Youyou was awarded the Nobel Prize for creating anti-malaria drug, using Traditional Chinese Medicine (TCM). Artemisinin, an active compound extracted from an aromatic herb sweet wormwood (which has been in use for treating malaria in China for more than 1,500 years now) was the key ingredient in preparing the prize-winning drug.

Based on herbs and other natural ingredients, the traditional medicines in China treat a range of health conditions, including common cold, pain, gastrointestinal ailments, and chronic illnesses, among others. TCM sector, fully supported by the Chinese government, has its own ecosystem in the country comprising dedicated practitioners, educational institutes, and the pharmaceutical companies manufacturing traditional medicine products.

1-TCM

Despite having been in use for more than 2,000 years (as claimed), domestic market for traditional medicines is smaller in comparison to that of conventional prescription and Over-The-Counter (OTC) drugs. The sector requires competitive TCM products for market expansion. However, this looks a distant possibility, as TCM-based clinical trials account for only about 5% of all trials (open studies) in China at present. This can be attributed to dearth of large organized TCM players with enough funds to invest in R&D. It also suggest that majority of Chinese consumers of traditional medicines rely on time-tested legacy preparations.

The State Council (the highest administrative body in China) meeting held in February 2016 asked for strengthening the sector through policy initiatives, such as increasing the number of traditional medicines in national essential medicine list, ensuring higher quality supervision (farm-to-factory), promoting modern production techniques, and consolidating a largely unorganized sector at supply side. The plan is also to support research and development and to look for ways to hasten industrialization and export of TCM.

Amid the urgency shown by the State Council, and in the light of recent Noble Award, it would be interesting to see if traditional medicines have the potential to provide alternative to conventional medicines at global stage, or will they largely remain a domestic (Chinese) phenomenon.

EOS Perspective

Though policy makers in China see enough potential still waiting to be tapped, the traditional medicines sector needs to overcome challenges in overseas as well as domestic market.

It is apparent that the Chinese government’s efforts to promote traditional medicines overseas in foreign markets have not yielded desired results. For instance, to boost TCM trade, the government announced a program in 2012 to establish 10 TCM trading centers worldwide. While there are no updates available on proposed plans to set up these TCM trade centers, in 2015, the first center of traditional Chinese medicine in Central and Eastern Europe was opened in a Czech hospital, as a pilot project.

The policy makers in China need to work around the fact that the expansion of traditional medicines beyond China is constrained due to doubts about their efficacy and possible side effects. One of the ways to allay fears of non-Chinese consumers (in order to ensure wider acceptance) is to get recognition through Western regulatory bodies, such as FDA. However, this can be a time consuming process, as evident from the history of TCM registrations outside China.

2-TCM Challenges

At present, the best approach seems to be to strengthen domestic TCM sector while identifying the TCM-friendly overseas markets and the therapeutic segments with potential to be successful abroad.

For competing at global level, TCM sector requires more TCM-focused companies, such as Dihon, Chinese herbal and OTC manufacturer (which was acquired by Bayer in 2014 with Bayer’s intent to strengthen its position in Chinese OTC market that currently consists of about 50% of herbal medicines). Dihon boasts of a strong TCM portfolio, including its star product Dan E Fu Kang, which is marketed as a gynecological medicine for women’s health indications. Dihon-like companies that have a few best-selling TCM drugs under their belt are exactly what the Chinese TCM sector needs in order to develop and expand abroad.

If successful, the envisaged state policies might lead to creation of a number of large TCM companies, with enough financial power to invest in research and development, thereby creating a robust traditional medicine portfolio. At present, only few known large players, such as Traditional Chinese Medicine Co. and Jiangsu Kanion Pharmaceutical, are operating in the Chinese market.

TCM sector’s international expansion should focus on OTC drugs with safety and success record proven in China, and introducing these drugs in markets where regulatory requirements for market approval are less stringent e.g. in Asia and Africa. Manufacturers of TCM can also look for complementing the existing conventional medicines (instead of replacing them) for life threatening diseases e.g. cancer. While not treating the actual disease, traditional medicines can contribute to providing a wholesome treatment. For instance, past studies in China suggest that TCM is effective in treating side effects, such as radiation injury and inflammation, nausea, and gastrointestinal disorders due to radio/chemotherapy.

It may take long for TCM to challenge conventional medicines and make commercial impact at global level. Till it happens, the traditional medicine market will remain China-centric. Only disruptive policy interventions will make the sector dominant at domestic level, thereby setting the stage for a global take-off.

by EOS Intelligence EOS Intelligence No Comments

BREXIT: First Thoughts

Streit ums Haus

In a landmark decision, UK’s citizen expressed their preference to leave the European Union. While the process is not straight forward, and will take at least two years to complete, Britain could struggle to lift the markets sentiment in a short to medium term.

Sterling Pound, probably one of the strongest currencies in the world, immediately suffered the largest drop in the past 30 years. Stock markets across the world have also responded to the news, with most stock exchanges witnessing a significant drop in share prices. This only reciprocates the negative market sentiment currently dominating the market. Some even feel that announcement of BREXIT could be a dawn a new recession period, similar to the 2008 crisis.

Britain will have to undergo massive negotiations over the next two years – not only in terms of their relations with other EU member countries, but also at a more granular level. Most companies will have to renegotiate their EU-wide contracts, to enable provisions for a separate/independent Britain. A major challenge will be addressing trade with EU member states, as well as countries with which EU has signed free trade agreements, which according to estimates puts about £250 billion worth of trade at risk.

Several companies, especially the ones which use Britain as the base to serve other EU markets, have been left in the midst of turbulent waters, unsure of what pans for them in the future. All will again depend on how negotiations go among the 27 EU member states during a long drawn process, after Britain enforces the Article 50 of the Treaty on European Union, for officially exiting the EU.

China, already suffering from the stock market and debt crisis in early 2016 following a crash in crude oil prices, could see its trade with European countries taking a hit. UK is the second largest customer for China in Europe. Weakening of the Sterling Pound and Euro is expected to erode the competitive advantage that China sought by devaluing its currency several times since August 2015. Moreover, the negative market sentiment is also likely to drive the crude oil prices further downwards, which could add the pressure on the debt-ridden country.

The knock-on effect will also be felt in other emerging markets in Asia. Nomura’s analysts predict growth rates in other Asian emerging markets to drop by up to 1.0 percentage point.

EOS Perspective

While many expect the impact of BREXIT to be felt gradually, the short terms scenario certainly seems to point otherwise. All will depend on how the exit process progresses, along with the negotiations, which might leave Britain in a slightly less advantageous position. Even if all goes well, it will take several years to attain normalcy.

by EOS Intelligence EOS Intelligence No Comments

Raising Customs Duty – The Right Prescription for India’s Bulk Drug Industry?

318views

Prescription and stethoscope.

India’s Drugs Technical Advisory Board (DTAB) has long expressed concerns over growing import of bulk drugs and over the challenges in ensuring the quality of the imported drugs. Hence, it came as no surprise when earlier this month (June 2016) the DTAB endorsed the Ministry of Health and Family Welfare’s (MoHFW) decision to increase customs duty on import of bulk drugs (APIs).

This also comes in the backdrop of India’s excessive reliance on China for its bulk drug requirement (including that for essential medicines) — ~70% of India’s bulk drugs come from China.

Chinese imports have already driven some Indian producers of bulk drugs (e.g. penicillin) out of business, and there are fears that Chinese producers may hike prices after destroying competition. China’s import influence is so strong that any event (such as Beijing Olympics of 2008 when several bulk drug plants in China were shut down to control pollution) could trigger tightening of supply to India, thus impacting domestic production.

The feeling in Indian government bodies is that unless China’s influence on India’s bulk drugs industry is curtailed, it might severely impact domestic growth prospects. By increasing customs duty, MoHFW’s aims (and hopes) to de-incentivize imports and create a level-playing field for domestic manufacturers of bulk drugs.

While DTAB’s move is welcomed by certain sections of India’s pharmaceuticals industry, the fact of the matter is that China still enjoys about 30-40% cost advantage vis-à-vis India in bulk drug manufacturing, making it a preferred import source, especially for manufacturers of essential medicines intending to save margins due to caps in retail pricing. It is unlikely that this advantage will change soon enough for India’s bulk drug industry to become self-sufficient.

In recent years, the Indian bulk drug industry has seen robust growth opportunities on account of off-patenting of several blockbuster drugs. The Associated Chambers of Commerce & Industry of India (ASSOCHAM) expects the bulk drugs industry to record a 12-14% CAGR growth during 2016-2019, driven by demand from manufacturers of off-patent drugs. So, while this move of increasing customs duty might boost growth of the local bulk drugs industry, this is only a small step towards promoting domestic production of bulk drugs.

On their part, India’s bulk drug manufacturers need to decide the basis of competition (specifically with their Chinese counterparts) i.e. cost vs. quality, niche vs. general formulations, regulated (markets with strict regulatory requirements and strong IP regime) vs. semi-regulated markets. Indian manufacturers stand a better chance by playing to their strength and focusing on developing quality products for regulated markets.

Government intervention is also required in the form of incentives, as recommended by the Katoch Committee (established in 2013 to look in to bulk drug industry issues), e.g. tax holidays, land for manufacturing at affordable rates, soft loans, etc., to enable cost-competitive domestic manufacturing. In December 2015, the government vowed to implement the Katoch Committee recommendations within 100 days (i.e. by April 2016). Since then there is no news (on public domain) regarding any development on this front.

It would be an overstatement to say that time is running out for the Indian bulk drugs industry. However, a time-bound action is the need of the hour to compete with China, which has a first-mover advantage (as far as favorable policies and pricing are concerned).

by EOS Intelligence EOS Intelligence No Comments

McDonald’s – Facing the Heat Globally

482views

With more than 36,000 outlets globally, out of which 14,000 are located in the USA alone, McDonald’s is rightly known as the fast-food giant. After decades of expansion that saw the brand conquer leading markets across the globe, McDonald’s seems to have been losing its sheen across leading markets since 2014, with the biggest challenge arising in its home market. Growing health consciousness among consumers, new diverse competition, legal hassles, and supply chain troubles have kept McDonald’s in the news for all the wrong reasons, while dropping profitability has forced this leading fast-food chain to shut down about 700 outlets globally in 2015 and further 500 in 2016. With a change in management and a proactive approach to upgrade its offerings, at least in its home market, the chain does seem to have a plan of action in place, however, it is yet to be seen if it is enough for damage control.

In an unprecedented step, McDonald’s (McD’s) shut down 700 outlets globally (350 outlets in the USA and 350 outlets in its remaining countries of operations) in 2015, and it expressed plans to shut down further 500 outlets globally in 2016. While the company maintains that this will help weed out unprofitable stores, it definitely does spell trouble for the world’s largest burger chain. The biggest concern, however, remains that the slowdown does not stem from poor performance in any one economy but an amalgamation of issues faced by the brand across the globe.

1-McDonald’s Struggles

2-McDonald’s Struggles

3-McDonald’s Struggles

As McD’s strides through one of its worst times, the company looks to tackle the dim outlook with a head-on approach. As one of the first steps, in March 2015, the company changed its management, appointing Steve Easterbook as CEO in place of Don Thompson (who served the company as CEO since July 2012. Since taking charge of the driving seat, Steve Easterbook (who was previously responsible for turning around the company’s business in the UK), has introduced several initiatives that seem to reinvent the brand offerings and reprise its lost reputation.

In the USA, the company introduced all day breakfast and introduced a new customizable menu called ‘TasteCrafted’ in nearly 700 outlets in the USA. The new menu is the company’s attempt to follow the Chipotle strategy of personalization of meals and presents consumers with the choice of three buns, three different meats, and three different styles of toppings. The company has also tried to tackle the minimum wage issue by raising wages in company-owned outlets in the USA, however, this created dissatisfaction among franchised outlets employees. However, even as a start, these measures have helped the company improve sales at home (US sales witnessed the first rise in two years in Q3 2015).

Internationally, and especially in Asia, the company is working towards stricter supply chain auditing to rebuild its brand image. In the Chinese market, the company has launched several healthier options such as apple slices, veggie cups, and multigrain muffins to attract the health-conscious consumers. McD’s is also looking at massive expansion in China, with plans to open about 250 new outlets each year over the next five years. It wants this next wave of growth to stir from the franchising model. Similarly, the company is looking at the prospects of selling a stake in its Japanese operations to a local investor, who could help the company turnaround its Japan business.

EOS Perspective

As McDonald’s woes seem to arise from a mix of dissatisfied stakeholders – consumers, partners, and employees across the globe that vary for each economy, it is not far-fetched to say that the company stands the risk of losing its leadership position across its top markets (as it already has in India). Several strategic decisions are being made by the brand to return to its past glory, however, these seem more long term in nature and therefore will have a significant gestation period before their results are visible.

While the company is largely looking to lean on franchising to spur growth and streamline operations, such as dependence on franchising can act as a double-edged sword especially in times when the company is facing tarnished reputation in several of its leading markets.

by EOS Intelligence EOS Intelligence No Comments

Solar Rises in the East

779views

The international solar arena which was once dominated by the developed countries in the West is now flaring in the emerging markets of Asia. We are looking at a holistic view of solar PV market across selected Asian countries – the finale of our series focusing on solar photovoltaic market landscape across selected Asian countries.


Our previous articles of the series took a detailed look into current scenario and future prospects of solar PV market in China (China’s Solar Power Boom), India (Solarizing India – Fad or Future?), Thailand (Utility-scale Projects to Boost Thai Solar Market), as well as Malaysia (Uncertainty Looms over Future of Solar PV Market in Malaysia).


 

Solar Rises in the East - Markets Overview - EOS IntelligenceSolar Rises in the East - Markets Are Moving Towards Solar Power - EOS IntelligenceSolar Rises in the East - Growth Drivers - EOS IntelligenceSolar Rises in the East - Growth Challenges (1) - EOS IntelligenceSolar Rises in the East - Growth Challenges (2) - EOS IntelligenceSolar Rises in the East - Opportunities - EOS IntelligenceSolar Rises in the East - Our Perspective - EOS Intelligence

by EOS Intelligence EOS Intelligence No Comments

Anatomy of a Bubble – Case Study: China

For years, China has been seen as a shining beacon amidst the global crisis, growing at a stunning pace while other countries reeled under the pressure of the global economic downturn of 2008-2009. However, Chinese stock market crashes, first in August 2015, and now at the start of 2016 have let people to question whether China is as immune to crisis as initially thought.

As per estimates by the Economist, Chinese equity market only impacts 15% of households. Therefore, the possibility of a widespread depression was quickly ruled out. However, there are other forces which are likely to be a greater cause of concern for the Chinese government, and possibly everyone around – the most prominent of them being the huge government and corporate debt bubble.

Looking at recent developments, there seems to be a striking resemblance between the increasingly swollen and inflated Chinese debt bubble and a simple spherical bubble, one that is impacted, shaped, and molded by a range of forces, as studied in school science books.

Slide1 - Forces Driving the Chinese Debt Bubble

Slide2 - Surface Tension

Slide3 - Government Measures

Slide4 - External Factors

EOS Perspective

China is under pressure in the face of rising labor costs, industrial overcapacity, falling prices, and weak global demand. Combination of economic slowdown, excess production in manufacturing, and rising debts at the macroeconomic level may cause a massive wave of firm closures and bad loans.

While China has expressed its intentions to reform its debt situation, internal and external market factors have forced the government to plunge more money into the market to finance economic growth and sustain the entire economy. These initiatives may diffuse the situation getting out of hand on a short-term basis. But the repercussion of a future debt crisis could be more severe. The scenario would not only be severe for China, but several other economies in the region, which are key sources of raw materials to China.

From a procurement point of view, while increasing price competition could make China still feature as an attractive proposition, buyers must consider the suppliers’ debt situation before making any decision. No one knows when, or if, the Chinese debt bubble will burst. With the situation still unclear, short-term contracts could be the way forward.

by EOS Intelligence EOS Intelligence No Comments

OEM Suppliers – Perfecting the Balancing Act

342views

Suppliers to the automotive industry (OEM suppliers) have witnessed strong and steady growth over the past few years. Owing largely to the recovery in the global automotive market coupled with high-capacity utilization at their production facilities, OEM suppliers have performed better as compared with their OEM customers, especially in terms of profitability. However, the golden period is expected to expire in the coming year. With automobile sales not rising at a similar pace as before (especially in developed markets), and growing pressure on OEMs’ margins, OEMs have been undertaking massive cost cutting programs. This in turn is putting pressure on OEM suppliers to reduce prices. Additionally, OEM suppliers are facing rising expectations from OEMs to be located close to the OEMs’ facilities, especially in emerging markets.

As the automotive industry is seeing a shaving off of sales and profits, it is increasingly exerting pressure on its suppliers. OEM suppliers are facing increased pressure from OEMs to have an increased global presence (closer to the OEMs’ own assembly lines). While this means expanding operations and investments, OEM suppliers also need to keep costs low to be competitive and meet OEMs cost reduction programs. Thus, OEM suppliers need to balance both these approaches to remain competitive.

1 - OEM Suppliers Industry Performance



2 - Balancing OEM Expectations



3 - Proximity to OEM Locations



4 - Cost Pressure from OEMs



5 - How to Manage Expectations


EOS Perspective

While the strategy for cutting costs and location proximity largely remain mutually exclusive, suppliers that best manage to meet their clients’ expectations have a chance to shine. They can look at innovative strategies such as locating themselves in a third region (that offers proximity to the clients site as well as offers low costs) to best balance client demands. But most importantly, suppliers need to device an optimal manufacturing network keeping in mind all aspects and overall cost/location benefits. Suppliers that manage to come up with innovative solutions to handle complex client requirements, are well likely to come out as industry winners during time when the industry maybe entering a crunch phase again.

by EOS Intelligence EOS Intelligence No Comments

China in 2016 – Time to Broaden the CV Horizon

The article was first published in Automotive World’s Guide to the automotive world in 2016.

—–

Whatever the current state of affairs in China, let’s be clear that the decline in commercial vehicle production and sales numbers is merely a speed bump and not a meltdown.

China still offers significant benefits in terms of continued internal investment in infrastructure and development, above average industry and trade sentiments, and GDP growth that is higher than in most other economies globally. Besides, as China moves towards a more consumer-oriented economy, the demand for goods and services locally will become the engine of automotive growth. Beyond China, there is a need for OEMs to look at other avenues of growth, be it export-driven or geographical expansion of production base.

In November 2014, as we were penning down our thoughts on how China’s automotive market is likely to shape up in 2015, we were concerned about market growth rates, anti-trust fines, role of local OEMs, and how China will sustain its dominance in the global auto market. As we progressed through 2015, everyone – OEMs, government, consumers, analysts – focused only on one aspect – China’s economic slowdown. Unfortunately, numbers validate that fear as we go into 2016.

While the story of passenger vehicles was more positive, with production and sales growing by 2.2% and 3.9% year-on-year, respectively, during the first 10 months of 2015, the production and sales of commercial vehicles during January-October 2015 declined by 11.3% and 10.6% year-on-year, respectively (as stated by China Association of Automobile Manufacturers). Figures for trucks were down 12.7% (production) and 11.9% (sales). There was some positive momentum in October, but not enough to make much impact on overall slowdown.

Will 2016 be any different for China’s CV market prospects? Unlikely. At best, the double-digit decline in production and sales that was seen in 2015 might come down to single-digit figures on a year-on-year basis, and we might see the market consolidating its position as the world’s CV factory. Growth apart, the bigger issue will be how OEMs manage inventory and production lines in 2016, and how OEMs restructure their operations to mitigate further risks of China’s slowdown.

EXPORT

Could exports be a way out for CV OEMs, to avoid getting slammed by China’s economic slowdown? Perhaps. 2016 might just be the year that OEMs with production base in China look at China as a serious export hub for the Southeast Asian region.

With several large scale infrastructure projects underway in the Southeast Asian region, the demand for CV, especially trucks is likely to be significant. Indonesia is a great example of how China could benefit from being an export hub of CVs. The country aims to complete over 300 major infrastructure projects including ports, railways and highways by 2025, and is likely to see a substantial demand for transport and construction vehicles. Similarly, the ambitious One Belt, One Road project and the establishment of the Asian Infrastructure Investment Bank (which aims to fund infrastructure construction in the region) are likely to provide a lucrative platform for China-based CV manufacturers to cater to the growing need for various commercial vehicles in the region. Vietnam, The Philippines, and Myanmar are not far away in terms of their infrastructure investment hunger, and have over the years displayed significant need for trucks, construction vehicles, and vehicles for public transportation.

Neighbouring India presents a very interesting opportunity as well. With the new government’s focus on infrastructure development, there is space for China-based CV OEMs to make their mark. Beiqi Foton and BeiBen are actively exploring this opportunity, in spite of severe competitive threat from Indian OEM powerhouses Tata, Mahindra & Mahindra, among others.

2016 might just be the right time to explore these opportunities and take the leap of faith. Those CV OEMs which are able to see the long-term benefits of expanding in this region, are likely to gain immensely.

EXPAND

Another area of interest in 2016, specifically for Chinese CV OEMs, might be looking at setting up production units in South America and Africa, with OEMs unlikely to invest further in their China operations to add capacity at this stage of excess inventory. Africa and South America have been steady partners over the last several years, accounting for over 50% of China’s CV exports.

A renewed look at prospects in South America (Brazil as a possible export hub to both South and Central America) and Africa with its growing appetite for infrastructure development, an area that China also has deep interests in, could provide an avenue of growth for Chinese OEMs given the strained economic conditions locally. These initiatives, however, should not be knee-jerk reactions to current issues with slowdown, but must be looked at from strategic long-term perspective.

ENERGISE

Back home, one wonders how the CV market will restructure itself. Local CV OEMs are clearly dominant, with few foreign OEMs managing to make their presence felt in the market. Various JVs in recent times have somewhat changed this picture, but the CV market is still quite fragmented. While there are a few specialised large OEMs operating across the value chain, one wonders if it is not the right time for further consolidation. There are a large number of small vulnerable manufacturers operating in the CV space, and perhaps some form of consolidation will help strengthen market dynamics.

The other aspect to consider, thanks to the imposition of stringent emissions standards, is how China’s CV market is slowly moving from price-focused purchase to product-focused purchase behaviour – 2016 might just be the starting point of China’s westernisation of CV market.


As we stand at the doors of 2016, it seems that OEMs have not one but several ways out of this slowdown. The question is if they have the risk appetite to make most of this downturn by expanding their presence beyond China – in both sales and production terms.

Top